|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
scroll down for analyst conference summary links
Analyst Conference: November 11, 2009 @ 1:30 PM Pacific Time
Analyst Day Summary [September 24, 2009]
Dendreon, the glory and the dream [June 23, 2009]
Dendreon Sells More Stock [Dendreon Press Release May 13, 2009]
Dendreon Press Release on First Quarter 2009 results [May 6, 2009]
Provenge Data Released to Analysts; Meets Prespecified Endpoint [April 28, 2009]
Provenge Demonstrates Statistically Significant Overall Survival [April 14, 2009]
Dendreon Gets Good Provenge Prostate Cancer Interim Results [October 6, 2008]
Data Point: FDA Cellular, Tissue and Gene Therapies Advisory Committee March 29, 2007 Draft Advisory Committee Questions on Provenge (Sipuleucel-T). This gives both the questions and the basic trial data that was submitted. This committee later recommended that the FDA approve Provenge, but the FDA instead issued an approvable letter.
2009 |
|||
 |
|
|
|
3/12/2009 |
08/11/2009 |
11/11/2009 |
|
Q4 2008 |
Q2 2009 |
Q3 2009 |
|
2008 |
|||
|
|
|
|
3/13/2008 |
05/08/2008 |
08/12/2008 |
11/7/2008 |
Q4 2007 |
Q1 2008 |
Q2 2008 |
Q3 2008 |
2007 |
|||
|
|
||
11/15/2007 |
08/07/2007 |
05/10/2007 |
11/08/2006 |
Q3 2007 |
Q2 2007 |
Q1 2007 |
Q4 2006 |
2006 |
|||
08/08/2006 |
05/09/2006 |
||
Q3 2006
|
Q2 2006 |
||
Dendreon Provenge Prostate Cancer Results Due Soon [September 14, 2008]
Provenge Interim Data Expected October 2008 [July 23, 2008]Waiting for Provenge [March 13, 2008]
Nature Biotechnology editorial on FDA's Provenge decision [January 2008]
CareToLive [The prostate cancer patients' site, who are pushing for approval of Provenge and an investigation of the FDA]
Dendreon Breast Cancer Results [August 19, 2007]
Summary of Conference re Latest FDA meeting [May 31, 2007]
Dendreon: There and Back Again [May 11, 2007]
Doctor Voices Dendreon Doubt [Forbes.com, April 26, 2007]
Dendreon Approvable Letter for Provenge [May 9, 2007]
What Price Dendreon? [April 12, 2007]
Dendreon Odds Less Long [March 30, 2007]
Dendreon is a biotechnology company specializing in creating immunotherapies for cancers. At this time its leading product, Provenge, has completed a Phase 3 trial with a reported successful outcome.
Dendreon Web site:
Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. Before making or terminating an investment you should always verify any factual basis of your decision from multiple independent sources.